pSivida Corp. Reports Alimera’s Intention to Resubmit Application to FDA for ILUVIEN® in DME Using Data from Completed Trials
08:15 EDT 1 Aug 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing
sustained release, drug delivery products for treatment of
back-of-the-eye diseases, today reported that its licensee Alimera
Sciences, Inc. has indicated its inten...
Other Sources for this Article
US Public Relations
Martin E. Janis & Company, Inc.
Beverly
Jedynak, +1 (312) 943 1123
President
bjedynak@janispr.com
or
pSivida
Corp.
Brian Leedman, +61 (0) 41 228 1780
Vice President,
Investor Relations
brianl@psivida.com
More From BioPortfolio on "pSivida Corp. Reports Alimera’s Intention to Resubmit Application to FDA for ILUVIEN® in DME Using Data from Completed Trials"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
